News ArchivesRead News
Scientists develop groundbreaking treatment for Parkinson's disease
Thursday April 12, 2012
Fox news.com - UK scientists believe they created a groundbreaking form of therapy that could revolutionize the way Parkinson's disease is treated.
One of the patients involved in the gene-therapy trial, Sheila Roy, says it was like turning back the clock 10 years.
She is one of only 15 people worldwide to have had the new treatment, which effectively creates a medicine factory in her brain.
Parkinson's disease occurs when the brain gradually stops producing the nerve-controlling chemical dopamine. Over time, symptoms such as tremors, slow movement and stiffness get worse.
ProSavin, the new treatment, uses a "stripped-down" virus to transport dopamine-making genes into the brain. It is injected into a region called the striatum that helps control movement.
Once the virus gets into the brain cells, it reprograms them to gradually start producing their own dopamine.
Roy was diagnosed with Parkinson's in her forties. After 17 years with the disease, she suffered from severe tremors, and a lack of balance made simple tasks such as writing impossible.
"People would take knives off me in the kitchen because I was everywhere with the knife," she said. "My vocal cords would suddenly shut so I can't breathe."
She added, "If I hit a wall of people, then I can't function -- I just stop -- but I'm starting to see a glimmer of the person I used to be, which is exciting."
Philip Buttery, from the Cambridge Centre for Brain Repair, in eastern England, said it was still early but that the treatment appears to be having positive results.
"It seems to be having an overall beneficial effect in smoothing out people's days, probably allowing a slight dose reduction in medication and, in some patients, a better sleep pattern and a better quality of life for all," he said.
It is not a cure, and more clinical trials are needed, he added.
The scientists at Oxford BioMedica, in southern England, also are developing gene therapy treatments for other degenerative illnesses.
Chief scientific officer Stuart Naylor said, "Rather than popping lots of tablets, the idea of a single shot therapy, single shot treatment, single shot placement of a gene therapy that provides that long-term therapeutic correction is something that hasn't been ever experienced before in medicine."
Recent NewsSep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 9 - Parkinson’s Experiment to Be Aboard Next Flight to International Space Station
Aug 9 - Parkinson’s Disease and Sleeping with the Enemy
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement